|
1
|
Liu X, Zeng L, Liu J, Huang Y, Yao H,
Zhong J, Tan J, Gao X, Xiong D and Liu L: Artesunate induces
ferroptosis in diffuse large B-cell lymphoma cells by targeting
PRDX1 and PRDX2. Cell Death Dis. 16:5132025. View Article : Google Scholar
|
|
2
|
Barraclough A, Hawkes E, Sehn LH and Smith
SM: Diffuse large B-cell lymphoma. Hematol Oncol. 42:e32022024.
View Article : Google Scholar
|
|
3
|
Liang XJ, Song XY, Wu JL, Liu D, Lin BY,
Zhou HS and Wang L: Advances in multi-omics study of prognostic
biomarkers of diffuse large B-cell lymphoma. Int J Biol Sci.
18:1313–1327. 2022. View Article : Google Scholar
|
|
4
|
Poletto S, Novo M, Paruzzo L, Frascione
PMM and Vitolo U: Treatment strategies for patients with diffuse
large B-cell lymphoma. Cancer Treat Rev. 110:1024432022. View Article : Google Scholar
|
|
5
|
International Non-Hodgkin's Lymphoma
Prognostic Factors Project: A predictive model for aggressive
non-Hodgkin's lymphoma. N Engl J Med. 329:987–994. 1993. View Article : Google Scholar
|
|
6
|
Hans CP, Weisenburger DD, Greiner TC,
Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, Campo E,
Braziel RM, Jaffe ES, et al: Confirmation of the molecular
classification of diffuse large B-cell lymphoma by
immunohistochemistry using a tissue microarray. Blood. 103:275–282.
2004. View Article : Google Scholar
|
|
7
|
Shen R, Fu D, Dong L, Zhang MC, Shi Q, Shi
ZY, Cheng S, Wang L, Xu PP and Zhao WL: Simplified algorithm for
genetic subtyping in diffuse large B-cell lymphoma. Signal
Transduct Target Ther. 8:1452023. View Article : Google Scholar
|
|
8
|
Wilcox RA, Wada DA, Ziesmer SC, Elsawa SF,
Comfere NI, Dietz AB, Novak AJ, Witzig TE, Feldman AL, Pittelkow MR
and Ansell SM: Monocytes promote tumor cell survival in T-cell
lymphoproliferative disorders and are impaired in their ability to
differentiate into mature dendritic cells. Blood. 114:2936–2944.
2009. View Article : Google Scholar
|
|
9
|
Shivakumar L and Ansell S: Targeting
B-lymphocyte stimulator/B-cell activating factor and a
proliferation-inducing ligand in hematologic malignancies. Clin
Lymphoma Myeloma. 7:106–108. 2006. View Article : Google Scholar
|
|
10
|
10.Shang CY, Wu JZ, Ren YM, Liang JH, Yin
H, Xia Y, Wang L, Li JY, Li Y and Xu W: Prognostic significance of
absolute monocyte count and lymphocyte to monocyte ratio in
mucosa-associated lymphoid tissue (MALT) lymphoma. Ann Hematol.
102:359–367. 2023. View Article : Google Scholar
|
|
11
|
Mohsen A, Taalab M, Abousamra N and Mabed
M: Prognostic significance of absolute lymphocyte count, absolute
monocyte count, and absolute lymphocyte count to absolute monocyte
count ratio in follicular non-hodgkin lymphoma. Clin Lymphoma
Myeloma Leuk. 20:e606–e615. 2020. View Article : Google Scholar
|
|
12
|
Conlan MG, Armitage JO, Bast M and
Weisenburger DD: Clinical significance of hematologic parameters in
non-Hodgkin's lymphoma at diagnosis. Cancer. 67:1389–1395. 1991.
View Article : Google Scholar
|
|
13
|
Jia WY and Zhang JJ: Effects of
glucocorticoids on leukocytes: Genomic and non-genomic mechanisms.
World J Clin Cases. 10:7187–7194. 2022. View Article : Google Scholar
|
|
14
|
Ugel S, Canè S, De Sanctis F and Bronte V:
Monocytes in the tumor microenvironment. Annu Rev Pathol.
16:93–122. 2021. View Article : Google Scholar
|
|
15
|
Arneth B: Complete blood count: Absolute
or relative values? J Hematol. 5:49–53. 2016. View Article : Google Scholar
|
|
16
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the eastern cooperative oncology group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar
|
|
17
|
Cheson BD, Fisher RI, Barrington SF,
Cavalli F, Schwartz LH, Zucca E, Lister TA; Alliance, Australasian
Leukaemia; Lymphoma Group and Eastern Cooperative Oncology Group, ;
et al: Recommendations for initial evaluation, staging, and
response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano
classification. J Clin Oncol. 32:3059–3068. 2014. View Article : Google Scholar
|
|
18
|
Zeng J, Zhang X, Jia L, Wu Y, Tian Y and
Zhang Y: Pretreatment lymphocyte-to-monocyte ratios predict
AIDS-related diffuse large B-cell lymphoma overall survival. J Med
Virol. 93:3907–3914. 2021. View Article : Google Scholar
|
|
19
|
Kharroubi DM, Nsouli G and Haroun Z:
Potential prognostic and predictive role of monocyte and lymphocyte
counts on presentation in patients diagnosed with diffuse large
B-cell lymphoma. Cureus. 15:e356542023.
|
|
20
|
Condamine T and Gabrilovich DI: Molecular
mechanisms regulating myeloid-derived suppressor cell
differentiation and function. Trends Immunol. 32:19–25. 2011.
View Article : Google Scholar
|
|
21
|
Yang F, Lee G and Fan Y: Navigating tumor
angiogenesis: Therapeutic perspectives and myeloid cell regulation
mechanism. Angiogenesis. 27:333–349. 2024. View Article : Google Scholar
|
|
22
|
Zha C, Yang X, Yang J, Zhang Y and Huang
R: Immunosuppressive microenvironment in acute myeloid leukemia:
Overview, therapeutic targets and corresponding strategies. Ann
Hematol. 103:4883–4899. 2024. View Article : Google Scholar
|
|
23
|
Kim JA, Kwak JY, Eunjung Y, Lee J, Park Y
and Broxmeyer HE: Fractalkine/CX3CR1 signaling promotes angiogenic
potentials in CX3CR1 expressing monocytes. Blood. 128:25072016.
View Article : Google Scholar
|
|
24
|
Song H, Chen L, Pan X, Shen Y, Ye M, Wang
G, Cui C, Zhou Q, Tseng Y, Gong Z, et al: Targeting tumor
monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing
STING agonist therapy. Cancer Cell. 43:503–518.e10. 2025.
View Article : Google Scholar
|
|
25
|
Le Gallou S, Lhomme F, Irish JM, Mingam A,
Pangault C, Monvoisin C, Ferrant J, Azzaoui I, Rossille D,
Bouabdallah K, et al: Nonclassical monocytes are prone to migrate
into tumor in diffuse large B-cell lymphoma. Front Immunol.
12:7556232021. View Article : Google Scholar
|
|
26
|
He B, Chadburn A, Jou E, Schattner EJ,
Knowles DM and Cerutti A: Lymphoma B cells evade apoptosis through
the TNF family members BAFF/BLyS and APRIL. J Immunol.
172:3268–3279. 2004. View Article : Google Scholar
|
|
27
|
Novak AJ, Grote DM, Stenson M, Ziesmer SC,
Witzig TE, Habermann TM, Harder B, Ristow KM, Bram RJ, Jelinek DF,
et al: Expression of BLyS and its receptors in B-cell non-Hodgkin
lymphoma: Correlation with disease activity and patient outcome.
Blood. 104:2247–2253. 2004. View Article : Google Scholar
|
|
28
|
Seiffert M, Schulz A, Ohl S, Döhner H,
Stilgenbauer S and Lichter P: Soluble CD14 is a novel
monocyte-derived survival factor for chronic lymphocytic leukemia
cells, which is induced by CLL cells in vitro and present at
abnormally high levels in vivo. Blood. 116:4223–4230. 2010.
View Article : Google Scholar
|
|
29
|
Davis RE, Ngo VN, Lenz G, Tolar P, Young
RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, et al:
Chronic active B-cell-receptor signalling in diffuse large B-cell
lymphoma. Nature. 463:88–92. 2010. View Article : Google Scholar
|
|
30
|
Liu T, Zhang L, Joo D and Sun SC: NF-κB
signaling in inflammation. Signal Transduct Target Ther.
2:170232017. View Article : Google Scholar
|
|
31
|
Steidl C, Lee T, Shah SP, Farinha P, Han
G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD, et al:
Tumor-associated macrophages and survival in classic Hodgkin's
lymphoma. N Engl J Med. 362:875–885. 2010. View Article : Google Scholar
|
|
32
|
Casey SC, Tong L, Li Y, Do R, Walz S,
Fitzgerald KN, Gouw AM, Baylot V, Gütgemann I, Eilers M and Felsher
DW: MYC regulates the antitumor immune response through CD47 and
PD-L1. Science. 352:227–231. 2016. View Article : Google Scholar
|
|
33
|
Kortlever RM, Sodir NM, Wilson CH,
Burkhart DL, Pellegrinet L, Brown Swigart L, Littlewood TD and Evan
GI: Myc cooperates with Ras by programming inflammation and immune
suppression. Cell. 171:1301–1315.e14. 2017. View Article : Google Scholar
|
|
34
|
Xu-Monette ZY, Wei L, Fang X, Au Q, Nunns
H, Nagy M, Tzankov A, Zhu F, Visco C, Bhagat G, et al: Genetic
subtyping and phenotypic characterization of the immune
microenvironment and MYC/BCL2 double expression reveal
heterogeneity in diffuse large B-cell lymphoma. Clin Cancer Res.
28:972–983. 2022. View Article : Google Scholar
|
|
35
|
von Hohenstaufen KA, Conconi A, de Campos
CP, Franceschetti S, Bertoni F, Margiotta CG, Stathis A, Ghielmini
M, Stussi G, Cavalli F, et al: Prognostic impact of monocyte count
at presentation in mantle cell lymphoma. Br J Haematol.
162:465–473. 2013. View Article : Google Scholar
|
|
36
|
Tadmor T, Bari A, Sacchi S, Marcheselli L,
Liardo EV, Avivi I, Benyamini N, Attias D, Pozzi S, Cox MC, et al:
Monocyte count at diagnosis is a prognostic parameter in diffuse
large B-cell lymphoma: Results from a large multicenter study
involving 1191 patients in the pre- and post-rituximab era.
Haematologica. 99:125–130. 2014. View Article : Google Scholar
|
|
37
|
Troppan KT, Melchardt T, Deutsch A,
Schlick K, Stojakovic T, Bullock MD, Reitz D, Beham-Schmid C, Weiss
L, Neureiter D, et al: The significance of pretreatment anemia in
the era of R-IPI and NCCN-IPI prognostic risk assessment tools: A
dual-center study in diffuse large B-cell lymphoma patients. Eur J
Haematol. 95:538–544. 2015. View Article : Google Scholar
|
|
38
|
Li M, Xia H, Zheng H, Li Y, Liu J, Hu L,
Li J, Ding Y, Pu L, Gui Q, et al: Red blood cell distribution width
and platelet counts are independent prognostic factors and improve
the predictive ability of IPI score in diffuse large B-cell
lymphoma patients. BMC Cancer. 19:10842019. View Article : Google Scholar
|
